Central Nervous System Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Application, By Route of Administration, By End User, By Distribution Channel, By Region & Competition, 2021-2031F

Description

The Global Central Nervous System Therapeutics Market is projected to expand from USD 115.21 billion in 2025 to USD 182.42 billion by 2031, reflecting a CAGR of 7.96%. These therapeutics consist of pharmaceutical interventions aimed at treating neurological and psychiatric conditions affecting the brain and spinal cord, such as Alzheimer's disease and depression. Key factors fueling this growth include rapidly aging global demographics and the resulting increase in neurodegenerative diseases, alongside a rising worldwide awareness of mental health issues that sustains demand for effective pharmacological treatments.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 115.21 Billion
Market Size 2031	USD 182.42 Billion
CAGR 2026-2031	7.96%
Fastest Growing Segment	Multiple Sclerosis
Largest Market	Asia Pacific

Conversely, the industry faces significant obstacles due to the scientific intricacies involved in developing drugs capable of crossing the blood-brain barrier, a hurdle that frequently contributes to high failure rates in clinical trials. This complexity leads to increased development costs and extended timelines, which can constrain market growth. Highlighting the massive financial resources dedicated to navigating these challenges, the European Federation of Pharmaceutical Industries and Associations estimated that the research-based pharmaceutical industry invested €55 billion in research and development across Europe in 2024.

Market Driver

The rising global prevalence of neurological and psychiatric disorders serves as the primary engine for growth in the Global Central Nervous System Therapeutics Market. As life expectancy rises, the cumulative risk of neurodegenerative conditions increases, creating a larger patient population requiring long-term pharmaceutical management, a trend further amplified by the widespread occurrence of mental health disorders that necessitate prioritized therapeutic access. The magnitude of this health crisis was highlighted by a study published in 'The Lancet Neurology' by the Institute for Health Metrics and Evaluation in March 2024, which estimated that over 3.4 billion people worldwide are affected by neurological conditions, making them the leading cause of global ill health and disability.

Concurrently, the market is boosted by a strong clinical pipeline and increased capital investment in neuroscience research and development. Pharmaceutical companies are actively pursuing strategic mergers and partnerships to acquire novel mechanisms of action, particularly for complex conditions like schizophrenia and Alzheimer's disease, thereby accelerating the commercialization of treatments and addressing barriers such as blood-brain barrier penetration. For instance, Bristol Myers Squibb agreed to acquire Karuna Therapeutics for an equity value of $14 billion in December 2023 to enhance its psychiatry portfolio, while the Alzheimer's Association projected in 2024 that total care payments for Americans with Alzheimer's and other dementias would reach $360 billion, underscoring the immense commercial potential for effective therapies.

Market Challenge

A major constraint on the global central nervous system therapeutics market is the scientific difficulty of creating drugs that can successfully traverse the blood-brain barrier. This biological filter selectively blocks many potential treatments from reaching targeted areas in the brain, resulting in exceptionally high attrition rates during clinical trials where compounds frequently fail to prove safety or efficacy in humans despite favorable preclinical data. Consequently, companies are compelled to lengthen development timelines and accept higher financial risks associated with neurological research initiatives.

The significant resources needed to manage these risks restrict the number of market participants and compress profit margins for successful drugs, creating hurdles for smaller entities and slowing the launch of new therapies. The severity of these challenges is evident in data from the Biotechnology Innovation Organization, which reported in 2024 that the clinical development success rate for new therapeutic candidates was approximately 6.7 percent. This low likelihood of approval tends to deter investment in CNS compared to therapeutic areas with higher success rates, thereby inhibiting the overall expansion of the market.

Market Trends

A pivotal transformation in the market is the shift toward disease-modifying biologics for neurodegenerative disorders, moving the focus from symptomatic relief to targeting underlying pathologies like Alzheimer's disease. This trend is led by the commercialization of anti-amyloid monoclonal antibodies capable of clearing plaque deposits and slowing cognitive decline, a development that is altering revenue models and spurring investment in diagnostic and infusion infrastructure. Reflecting the rapid uptake of these therapies, Eisai Co., Ltd. projected in a November 2024 press release that global revenue for its Alzheimer's treatment, Leqembi, would reach JPY 42.5 billion for the fiscal year ending March 2025.

Simultaneously, the adoption of artificial intelligence for CNS target identification is expediting the discovery of viable drug candidates and addressing historic failure rates in neurological development. Pharmaceutical firms are increasingly collaborating with AI-specialized companies to utilize machine learning algorithms that analyze massive biological datasets, enabling precise prediction of drug-target interactions and optimization of molecular structures prior to clinical testing. Demonstrating the significant capital flowing into this area, Formation Bio announced in a June 2024 press release that it secured $372 million in Series D financing, with participation from Sanofi, to enhance its AI-driven drug development capabilities.

Key Market Players

Pfizer Inc.
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Novartis International AG
Roche Holding AG
Bristol-Myers Squibb Company
Sanofi S.A.
GlaxoSmithKline plc
AbbVie Inc.
AstraZeneca plc

Report Scope

In this report, the Global Central Nervous System Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Central Nervous System Therapeutics Market, By Drug Class

Multiple Sclerosis
Antipsychotic
Antiepileptics
Analgesics & Anesthetics
Anti-Parkinson
Others

Central Nervous System Therapeutics Market, By Application

Neurodegenerative Diseases
Mental Health and Trauma
Neurovascular Diseases
Infectious Diseases
CNS Cancer
Others

Central Nervous System Therapeutics Market, By Route of Administration

Oral
Parenteral
Others

Central Nervous System Therapeutics Market, By End User

Hospital
Clinics
Diagnostic Laboratories
Others

Central Nervous System Therapeutics Market, By Distribution Channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Central Nervous System Therapeutics Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Central Nervous System Therapeutics Market.

Available Customizations:

Global Central Nervous System Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Central Nervous System Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class (Multiple Sclerosis, Antipsychotic, Antiepileptics, Analgesics & Anesthetics, Anti-Parkinson, Others)
- 5.2.2. By Application (Neurodegenerative Diseases, Mental Health and Trauma, Neurovascular Diseases, Infectious Diseases, CNS Cancer, Others)
- 5.2.3. By Route of Administration (Oral, Parenteral, Others)
- 5.2.4. By End User (Hospital, Clinics, Diagnostic Laboratories, Others)
- 5.2.5. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
- 5.2.6. By Region
- 5.2.7. By Company (2025)
5.3. Market Map

6. North America Central Nervous System Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Application
- 6.2.3. By Route of Administration
- 6.2.4. By End User
- 6.2.5. By Distribution Channel
- 6.2.6. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Central Nervous System Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Application
    - 6.3.1.2.3. By Route of Administration
    - 6.3.1.2.4. By End User
    - 6.3.1.2.5. By Distribution Channel
- 6.3.2. Canada Central Nervous System Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Application
    - 6.3.2.2.3. By Route of Administration
    - 6.3.2.2.4. By End User
    - 6.3.2.2.5. By Distribution Channel
- 6.3.3. Mexico Central Nervous System Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Application
    - 6.3.3.2.3. By Route of Administration
    - 6.3.3.2.4. By End User
    - 6.3.3.2.5. By Distribution Channel

7. Europe Central Nervous System Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Application
- 7.2.3. By Route of Administration
- 7.2.4. By End User
- 7.2.5. By Distribution Channel
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Central Nervous System Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Application
    - 7.3.1.2.3. By Route of Administration
    - 7.3.1.2.4. By End User
    - 7.3.1.2.5. By Distribution Channel
- 7.3.2. France Central Nervous System Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Application
    - 7.3.2.2.3. By Route of Administration
    - 7.3.2.2.4. By End User
    - 7.3.2.2.5. By Distribution Channel
- 7.3.3. United Kingdom Central Nervous System Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Application
    - 7.3.3.2.3. By Route of Administration
    - 7.3.3.2.4. By End User
    - 7.3.3.2.5. By Distribution Channel
- 7.3.4. Italy Central Nervous System Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Application
    - 7.3.4.2.3. By Route of Administration
    - 7.3.4.2.4. By End User
    - 7.3.4.2.5. By Distribution Channel
- 7.3.5. Spain Central Nervous System Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Application
    - 7.3.5.2.3. By Route of Administration
    - 7.3.5.2.4. By End User
    - 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Central Nervous System Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Application
- 8.2.3. By Route of Administration
- 8.2.4. By End User
- 8.2.5. By Distribution Channel
- 8.2.6. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Central Nervous System Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Application
    - 8.3.1.2.3. By Route of Administration
    - 8.3.1.2.4. By End User
    - 8.3.1.2.5. By Distribution Channel
- 8.3.2. India Central Nervous System Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Application
    - 8.3.2.2.3. By Route of Administration
    - 8.3.2.2.4. By End User
    - 8.3.2.2.5. By Distribution Channel
- 8.3.3. Japan Central Nervous System Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Application
    - 8.3.3.2.3. By Route of Administration
    - 8.3.3.2.4. By End User
    - 8.3.3.2.5. By Distribution Channel
- 8.3.4. South Korea Central Nervous System Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Class
    - 8.3.4.2.2. By Application
    - 8.3.4.2.3. By Route of Administration
    - 8.3.4.2.4. By End User
    - 8.3.4.2.5. By Distribution Channel
- 8.3.5. Australia Central Nervous System Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Class
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By Route of Administration
    - 8.3.5.2.4. By End User
    - 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Central Nervous System Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Application
- 9.2.3. By Route of Administration
- 9.2.4. By End User
- 9.2.5. By Distribution Channel
- 9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Central Nervous System Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Application
    - 9.3.1.2.3. By Route of Administration
    - 9.3.1.2.4. By End User
    - 9.3.1.2.5. By Distribution Channel
- 9.3.2. UAE Central Nervous System Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Application
    - 9.3.2.2.3. By Route of Administration
    - 9.3.2.2.4. By End User
    - 9.3.2.2.5. By Distribution Channel
- 9.3.3. South Africa Central Nervous System Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Application
    - 9.3.3.2.3. By Route of Administration
    - 9.3.3.2.4. By End User
    - 9.3.3.2.5. By Distribution Channel

10. South America Central Nervous System Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Application
- 10.2.3. By Route of Administration
- 10.2.4. By End User
- 10.2.5. By Distribution Channel
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Central Nervous System Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Application
    - 10.3.1.2.3. By Route of Administration
    - 10.3.1.2.4. By End User
    - 10.3.1.2.5. By Distribution Channel
- 10.3.2. Colombia Central Nervous System Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Application
    - 10.3.2.2.3. By Route of Administration
    - 10.3.2.2.4. By End User
    - 10.3.2.2.5. By Distribution Channel
- 10.3.3. Argentina Central Nervous System Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Application
    - 10.3.3.2.3. By Route of Administration
    - 10.3.3.2.4. By End User
    - 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Central Nervous System Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Pfizer Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Eli Lilly and Company
15.3. Johnson & Johnson Services, Inc.
15.4. Novartis International AG
15.5. Roche Holding AG
15.6. Bristol-Myers Squibb Company
15.7. Sanofi S.A.
15.8. GlaxoSmithKline plc
15.9. AbbVie Inc.
15.10. AstraZeneca plc